---
title: "Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295448020.md"
description: "Progressing a novel once-daily oral prodrug PDE4 inhibitor, optimized for local activation, to potentially become a top choice for treating inflammatory bowel disease (IBD)."
datetime: "2026-08-10T20:21:45.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295448020.md)
  - [en](https://longbridge.com/en/news/295448020.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295448020.md)
generator: "portal-rs"
---

# Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development

Progressing a novel once-daily oral prodrug PDE4 inhibitor, optimized for local activation, to potentially become a top choice for treating inflammatory bowel disease (IBD).

### Related Stocks

- [PALI.US](https://longbridge.com/en/quote/PALI.US.md)

## Related News & Research

- [Palisade Bio Q2 net loss widens on higher R&D costs](https://longbridge.com/en/news/295446808.md)
- [Palisade Bio Draws Bullish Call, Lead IBD Drug Advances Toward Phase 2](https://longbridge.com/en/news/293653896.md)
- [TipRanks Analyst Salveen Richter Reiterates Buy on Braveheart Bio, Sets $48 12-Month Target on Strong HCM Opportunity for Lead Asset BHB-1893](https://longbridge.com/en/news/297471640.md)
- [Red Robin completes sale of 108 restaurants for $89.4 million in refranchising deals](https://longbridge.com/en/news/297691937.md)
- [FY2030 EPS Estimates for Palisade Bio Reduced by Analyst](https://longbridge.com/en/news/296061307.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**